Clinical trials: Apixaban, completed
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Stroke, Atrial Fibrillation
Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation
A retrospective cohort study of Thai octogenarians with nonvalvular atrial fibrillation (NVAF) initiating apixaban, dabigatran, rivaroxaban or warfarin was conducted in medical school hospital in Thailand.
- Trial name
- NCT04047654
- Testing
- Non vitamin K oral anticoagulants
- Where
- Thailand
- Volunteers
- 327 people
- Sponsor
- Mahidol University
Anticoagulants, Thromboembolism
Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
Vitamin K antagonists were hampered by several disadvantages, such as the need for frequent monitoring. In this context, new oral anticoagulants (NOACs) have been developed and are now available on the market.
- Conditions
- Anticoagulants, Thromboembolism, Hemorrhage
- Trial name
- Pgp NACO (NCT02103101)
- Testing
- Measurement of Plasma Concentrations of NOACs, Identification of ABCB1 polymorphisms coding for P-gp
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
N/A - Healthy Subjects
Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects
The purpose of this study is to assess the effects of Apixaban on the Pharmacokinetics (PK) of multiple-dose Digoxin in healthy subjects.
- Trial name
- NCT02262520
- Testing
- Apixaban, Digoxin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Multiple Myeloma
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs).
- Trial name
- NCT02958969
- Testing
- Apixaban
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gregory Piazza
Atrial Fibrillation
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart.
- Trial name
- EMANATE (NCT02100228)
- Testing
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Where
- 165 sites in United States, Belgium and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Pfizer
Pulmonary Embolism
The PEERLESS II Study
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
- Trial name
- NCT06055920
- Testing
- FlowTriever System, Anticoagulation Agents
- Where
- 72 sites in United States, Belgium and 6 more
- Volunteers
- 1,200 people
- Sponsor
- Inari Medical
Non-Valvular Atrial Fibrillation
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin…
- Trial name
- ARISTOPHANES (NCT03087487)
- Where
- United States
- Volunteers
- 466,991 people
- Sponsor
- Bristol-Myers Squibb
Bariatric Surgery, Obesity
Apixaban Pharmacokinetics in Bariatric Patients (APB)
The Center for Bariatric Surgery is interested in conducting a pharmacokinetic study of apixaban (an oral anticoagulant with FDA approval for use of venous thrombo embolism (VTE) prophylaxis and treatment) in the obese adult…
- Trial name
- APB (NCT02406885)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Healthy
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood…
- Trial name
- NCT03288454
- Testing
- Ciraparantag, Apixaban
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Venous Thromboembolism
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
- Trial name
- VTE (NCT04041843)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Atrial Fibrillation
Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)
Oral anticoagulant (OAC) treatment with either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) is essential in patients with atrial fibrillation for the prevention of stroke or systemic…
- Trial name
- REATTAIN (NCT04249401)
- Testing
- Rivaroxaban (Xarelto), Apixaban, Dabigatran
- Where
- Sweden
- Volunteers
- 134,897 people
- Sponsor
- Bayer
Atrial Fibrillation, End Stage Renal Failure on Dialysis
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis
The prevention of atrial fibrillation related thromboembolism in the dialysis population is unclear. While the practice of anticoagulation appears favorable in patients with mild-to-moderate chronic kidney disease, no patients…
- Trial name
- SAFE-D (NCT03987711)
- Testing
- Warfarin, Apixaban, No oral anticoagulation
- Where
- 28 sites in Australia, Canada
- Volunteers
- 151 people
- Sponsor
- Unity Health Toronto
Periprocedural Complication
Periprocedural Direct Oral Anticoagulant Management
Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between others.
- Trial name
- RA-ACOD (NCT03182218)
- Testing
- Direct oral anticoagulant
- Where
- 30 sites in Spain
- Volunteers
- 1,100 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk…
- Trial name
- OSCAR-US (NCT04979780)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Where
- United States
- Volunteers
- 3,708 people
- Sponsor
- Bayer
Atrial Fibrillation, End-stage Kidney Disease
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA) phenprocoumon in patients with NVAF and ESKD…
- Trial name
- AXADIA (NCT02933697)
- Testing
- Apixaban, Phenprocoumon
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Atrial Fibrillation Network
Thromboembolism
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin.
- Trial name
- NCT05643885
- Where
- United States
- Volunteers
- 7,304 people
- Sponsor
- Pfizer
Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis
DOAC in Unusual Site Venous Thrombosis
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein…
- Conditions
- Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis
- Trial name
- DUST (NCT03778502)
- Testing
- Direct Oral Anticoagulants
- Where
- 24 sites in United States, Canada and 8 more
- Volunteers
- 358 people
- Sponsor
- University of Malta
Atrial Fibrillation
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
- Trial name
- NCT02754154
- Testing
- Warfarin, Apixaban, Dabigatran
- Volunteers
- 321,182 people
- Sponsor
- Bristol-Myers Squibb